-
841
Image 5_A zebrafish model of crim1 loss of function has small and misshapen lenses with dysregulated clic4 and fgf1b expression.tiff
Published 2025“…</p>Results<p>Homozygous, crim1<sup>−/−</sup> larvae demonstrated smaller eyes and small and misshapen lenses compared to controls, but we did not observe colobomas. …”
-
842
Table 2_A zebrafish model of crim1 loss of function has small and misshapen lenses with dysregulated clic4 and fgf1b expression.docx
Published 2025“…</p>Results<p>Homozygous, crim1<sup>−/−</sup> larvae demonstrated smaller eyes and small and misshapen lenses compared to controls, but we did not observe colobomas. …”
-
843
Data Sheet 1_The flavonoid of Dracocephalum heterophyllum Benth. ameliorates cerebral small vessel disease by inhibiting the autophagy via Angs-Tie2 signaling pathway.docx
Published 2025“…Background<p>Cerebral small vessel disease (CSVD) is a common cause of stroke and vascular cognitive impairment. …”
-
844
-
845
Table 1_Bevacizumab and anlotinib combination therapy acts via HIF-1α suppression to exert synergistic anti-angiogenic and anti-tumor effects in non-small cell lung cancer.docx
Published 2025“…Introduction<p>Tumor angiogenesis is required for the progression of non-small cell lung cancer (NSCLC), and anti-vascular endothelial growth factor (anti-VEGF) antibody bevacizumab and multitarget tyrosine kinase inhibitor anlotinib are anti-cancer treatment options, the combined effect of which in NSCLC remains unclear.…”
-
846
Data Sheet 2_Bevacizumab and anlotinib combination therapy acts via HIF-1α suppression to exert synergistic anti-angiogenic and anti-tumor effects in non-small cell lung cancer.pdf...
Published 2025“…Introduction<p>Tumor angiogenesis is required for the progression of non-small cell lung cancer (NSCLC), and anti-vascular endothelial growth factor (anti-VEGF) antibody bevacizumab and multitarget tyrosine kinase inhibitor anlotinib are anti-cancer treatment options, the combined effect of which in NSCLC remains unclear.…”
-
847
Data Sheet 1_Bevacizumab and anlotinib combination therapy acts via HIF-1α suppression to exert synergistic anti-angiogenic and anti-tumor effects in non-small cell lung cancer.zip...
Published 2025“…Introduction<p>Tumor angiogenesis is required for the progression of non-small cell lung cancer (NSCLC), and anti-vascular endothelial growth factor (anti-VEGF) antibody bevacizumab and multitarget tyrosine kinase inhibitor anlotinib are anti-cancer treatment options, the combined effect of which in NSCLC remains unclear.…”
-
848
-
849
-
850
-
851
-
852
-
853
-
854
-
855
No signs of toxicity of HIFN treatment were reported in the histopathological analysis.
Published 2025Subjects: -
856
Serum chemistry in the animals after chronic treatment with HIFN or vehicle.
Published 2025Subjects: -
857
Image 2_Spatial deciphering of the transcriptomic heterogeneity of tumor spread through air spaces in lung cancer.tif
Published 2025“…Meanwhile, an increase in CD4 T memory cells and a decrease in B cells were observed in the tumor immune microenvironment of STAS. …”
-
858
Image 4_Spatial deciphering of the transcriptomic heterogeneity of tumor spread through air spaces in lung cancer.tif
Published 2025“…Meanwhile, an increase in CD4 T memory cells and a decrease in B cells were observed in the tumor immune microenvironment of STAS. …”
-
859
Data Sheet 1_Spatial deciphering of the transcriptomic heterogeneity of tumor spread through air spaces in lung cancer.zip
Published 2025“…Meanwhile, an increase in CD4 T memory cells and a decrease in B cells were observed in the tumor immune microenvironment of STAS. …”
-
860
Image 1_Spatial deciphering of the transcriptomic heterogeneity of tumor spread through air spaces in lung cancer.tif
Published 2025“…Meanwhile, an increase in CD4 T memory cells and a decrease in B cells were observed in the tumor immune microenvironment of STAS. …”